KoBioLabs Overview
- Year Founded
-
2014

- Status
-
Public
- Employees
-
51

- Stock Symbol
-
348150

- Investments
-
1
- Share Price
-
$3.33
- (As of Friday Closing)
KoBioLabs General Information
Description
KoBioLabs Inc is a biotechnology company focused on Microbiome therapeutics. It is involved in the research of medicines for Immune, Metabolic and Neurological Diseases.
Contact Information
Website
www.kobiolabs.comCorporate Office
- 7F, Building C, Daewangpangyo-ro
- Bundang-gu
- Seongnam-si, Gyeonggi-do 13488
- South Korea
Corporate Office
- 7F, Building C, Daewangpangyo-ro
- Bundang-gu
- Seongnam-si, Gyeonggi-do 13488
- South Korea
KoBioLabs Stock Performance
As of 07-Feb-2025, KoBioLabs’s stock price is $3.33. Its current market cap is $64.6M with 19.3M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$3.33 | $3.41 | $3.14 - $7.62 | $64.6M | 19.3M | 61K | -$0.37 |
KoBioLabs Financials Summary
As of 30-Sep-2024, KoBioLabs has a trailing 12-month revenue of $45.6M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 78,737 | 95,943 | 104,748 | 215,594 |
Revenue | 45,552 | 25,346 | 8,982 | 2,526 |
EBITDA | (6,070) | (11,387) | (17,470) | (14,390) |
Net Income | (7,039) | (10,595) | (16,965) | (13,429) |
Total Assets | 79,610 | 88,946 | 98,130 | 88,474 |
Total Debt | 12,585 | 14,196 | 10,913 | 7,728 |
KoBioLabs Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
KoBioLabs Patents
KoBioLabs Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230293600-A1 | Faecalibacterium prausnitzii strain and uses there of | Pending | 14-Aug-2020 | ||
EP-4201415-A1 | Faecalibacterium prausnitzii strain and uses thereof | Pending | 14-Aug-2020 | ||
EP-4201415-A4 | Faecalibacterium prausnitzii strain and uses thereof | Pending | 14-Aug-2020 | ||
US-20230173019-A1 | Protein variant having glp-1 inducing activity and use thereof | Pending | 24-Apr-2020 | ||
EP-4141023-A1 | Protein variant having glp-1 inducing activity and use thereof | Pending | 24-Apr-2020 | A61K38/16 |
KoBioLabs Signals
KoBioLabs Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
KoBioLabs Investments (1)
KoBioLabs’s most recent deal was a Joint Venture with WeBiom. The deal was made on 01-Mar-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
WeBiom | 01-Mar-2022 | Joint Venture | Pharmaceuticals |
KoBioLabs ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
38.04 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,784
Rank
Percentile

Pharmaceuticals
Industry
of 955
Rank
Percentile

Biotechnology
Subindustry
of 440
Rank
Percentile

KoBioLabs FAQs
-
When was KoBioLabs founded?
KoBioLabs was founded in 2014.
-
Where is KoBioLabs headquartered?
KoBioLabs is headquartered in Seongnam-si, South Korea.
-
What is the size of KoBioLabs?
KoBioLabs has 51 total employees.
-
What industry is KoBioLabs in?
KoBioLabs’s primary industry is Drug Discovery.
-
Is KoBioLabs a private or public company?
KoBioLabs is a Public company.
-
What is KoBioLabs’s stock symbol?
The ticker symbol for KoBioLabs is 348150.
-
What is the current stock price of KoBioLabs?
As of 07-Feb-2025 the stock price of KoBioLabs is $3.33.
-
What is the current market cap of KoBioLabs?
The current market capitalization of KoBioLabs is $64.6M.
-
What is KoBioLabs’s current revenue?
The trailing twelve month revenue for KoBioLabs is $45.6M.
-
What is KoBioLabs’s annual earnings per share (EPS)?
KoBioLabs’s EPS for 12 months was -$0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »